PMID- 22555448
OWN - NLM
STAT- MEDLINE
DCOM- 20120719
LR  - 20120504
IS  - 1473-6527 (Electronic)
IS  - 0951-7375 (Linking)
VI  - 25
IP  - 3
DP  - 2012 Jun
TI  - Helicobacter pylori infection: what's new.
PG  - 337-44
LID - 10.1097/QCO.0b013e3283531f7c [doi]
AB  - PURPOSE OF REVIEW: This review is aimed at describing the main findings of 2011 
      on the aspects of Helicobacter pylori-related gastric disease linked to CagA and 
      to T-regulatory cells (Treg), and on the attempts to improve the treatment 
      efficacy. RECENT FINDINGS: Recent findings presented in this review are as 
      follows: CagA interferes with tumor suppression; tolerance protects from H. 
      pylori-induced disease; modified H. pylori treatments/regimens can afford higher 
      efficacy than the standard triple therapy. SUMMARY: H. pylori colonizes the human 
      stomach causing gastritis and severe diseases including gastric cancer. One of 
      the most dangerous H. pylori factors, CagA, has been investigated in relation to 
      gastric cancer: recently this relationship was strongly reinforced by the finding 
      that CagA interacts with the tumor suppressor apoptosis-stimulating protein of 
      p53-2 (ASPP2), promoting p53 degradation. Treg have been proposed to be involved 
      in H. pylori infection and gastric disease: recent findings suggest that 
      Treg-induced tolerance, rather than immunity to H. pylori, may result in less 
      severe disease. The eradication rates achieved with the standard triple therapy 
      dropped below 80%, mainly due to antibiotic resistance, while no vaccines are 
      currently licensed; new treatments/regimens were subjected to clinical trials, in 
      some cases strongly increasing the eradication rates.
FAU - Ruggiero, Paolo
AU  - Ruggiero P
AD  - Novartis Vaccines and Diagnostics Srl, Siena, Italy. paolo.ruggiero@novartis.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Infect Dis
JT  - Current opinion in infectious diseases
JID - 8809878
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (TP53BP2 protein, human)
RN  - 0 (cagA protein, Helicobacter pylori)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antigens, Bacterial/*physiology
MH  - Apoptosis Regulatory Proteins/metabolism
MH  - Bacterial Proteins/*physiology
MH  - Bacterial Vaccines/administration & dosage
MH  - Drug Therapy, Combination
MH  - Gastritis/drug therapy/immunology/*microbiology
MH  - *Helicobacter Infections/immunology/physiopathology/therapy
MH  - Helicobacter pylori/*chemistry
MH  - Humans
MH  - Immunotherapy/methods
MH  - Proton Pump Inhibitors/therapeutic use
EDAT- 2012/05/05 06:00
MHDA- 2012/07/20 06:00
CRDT- 2012/05/05 06:00
PHST- 2012/05/05 06:00 [entrez]
PHST- 2012/05/05 06:00 [pubmed]
PHST- 2012/07/20 06:00 [medline]
AID - 00001432-201206000-00015 [pii]
AID - 10.1097/QCO.0b013e3283531f7c [doi]
PST - ppublish
SO  - Curr Opin Infect Dis. 2012 Jun;25(3):337-44. doi: 10.1097/QCO.0b013e3283531f7c.